CryoCell International Inc (CCEL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CryoCell International Inc (CCEL) has a cash flow conversion efficiency ratio of -0.171x as of August 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.54 Million) by net assets ($-14.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CryoCell International Inc (CCEL) net asset quality to measure how much of total assets are equity-financed.
CryoCell International Inc - Cash Flow Conversion Efficiency Trend (1996–2024)
This chart illustrates how CryoCell International Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check CryoCell International Inc (CCEL) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CryoCell International Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CryoCell International Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Trident Digital Tech Holdings Ltd American Depository Shares
NASDAQ:TDTH
|
0.658x |
|
Progressive Planet Solutions Inc
V:PLAN
|
0.088x |
|
Hudson Acquisition I Corp. Common Stock
NASDAQ:HUDA
|
0.012x |
|
Niche Capital Emas Holdings
KLSE:7139
|
0.013x |
|
Lotus Eye Hospital and Institute Limited
NSE:LOTUSEYE
|
0.008x |
|
DIOSTECH Co.Ltd
KQ:196450
|
-0.140x |
|
KPS Consortium Bhd
KLSE:9121
|
0.004x |
|
Samil Enterprise Co. Ltd
KQ:002290
|
0.033x |
Annual Cash Flow Conversion Efficiency for CryoCell International Inc (1996–2024)
The table below shows the annual cash flow conversion efficiency of CryoCell International Inc from 1996 to 2024. For the full company profile with market capitalisation and key ratios, see CryoCell International Inc (CCEL) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-11-30 | $-13.22 Million | $6.01 Million | -0.455x | +43.75% |
| 2023-11-30 | $-11.03 Million | $8.92 Million | -0.809x | +85.62% |
| 2022-11-30 | $-1.52 Million | $8.57 Million | -5.624x | -396.90% |
| 2021-11-30 | $4.18 Million | $7.93 Million | 1.894x | +159.63% |
| 2020-11-30 | $-2.67 Million | $8.47 Million | -3.177x | -249.31% |
| 2019-11-30 | $-6.95 Million | $6.32 Million | -0.909x | -51.90% |
| 2018-11-30 | $-8.91 Million | $5.33 Million | -0.599x | -30.91% |
| 2017-11-30 | $-12.50 Million | $5.72 Million | -0.457x | -41.33% |
| 2016-11-30 | $-15.41 Million | $4.99 Million | -0.324x | +66.89% |
| 2015-11-30 | $-4.96 Million | $4.85 Million | -0.977x | -574.23% |
| 2014-11-30 | $-10.73 Million | $1.55 Million | -0.145x | -63.43% |
| 2013-11-30 | $-9.27 Million | $821.98K | -0.089x | -121.12% |
| 2012-11-30 | $-9.00 Million | $360.90K | -0.040x | +87.95% |
| 2011-11-30 | $-2.46 Million | $819.12K | -0.333x | +77.92% |
| 2010-11-30 | $-1.55 Million | $2.34 Million | -1.508x | -108.48% |
| 2009-11-30 | $-5.18 Million | $3.75 Million | -0.723x | -721.95% |
| 2008-11-30 | $-6.98 Million | $614.16K | -0.088x | -117.04% |
| 2007-11-30 | $-6.59 Million | $-3.40 Million | 0.517x | +216.84% |
| 2006-11-30 | $-2.09 Million | $924.90K | -0.442x | -105.42% |
| 2005-11-30 | $394.56K | $3.22 Million | 8.157x | +246.69% |
| 2004-11-30 | $-835.75K | $4.65 Million | -5.561x | -1359.26% |
| 2003-11-30 | $-3.79 Million | $-1.67 Million | 0.442x | +2061.91% |
| 2002-11-30 | $9.87 Million | $201.56K | 0.020x | -76.42% |
| 2001-11-30 | $14.52 Million | $1.26 Million | 0.087x | +139.99% |
| 2000-11-30 | $6.64 Million | $239.53K | 0.036x | +136.10% |
| 1999-11-30 | $5.00 Million | $-500.00K | -0.100x | +85.63% |
| 1998-11-30 | $2.30 Million | $-1.60 Million | -0.696x | -115.65% |
| 1997-11-30 | $3.10 Million | $-1.00 Million | -0.323x | -199.46% |
| 1996-11-30 | $3.70 Million | $1.20 Million | 0.324x | -- |
About CryoCell International Inc
Cryo-Cell International, Inc. engages in cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells, which are used in regenerative medicine to treat a range of conditions. The company manu… Read more